medigraphic.com
ISSN 2992-779X (Digital)
ISSN 2007-6452 (Impreso)

2025, Número 3

Siguiente >>

Investigación en Discapacidad 2025; 11 (3)


Análisis de la línea celular del tumor de células gigantes del hueso TIB 223 sobre el efecto de la quercetina

Monroy QDL, Luna AAB, Rocío AGM, Santamaría OMG, Hidalgo-Bravo A, Sánchez CL, Estrada VEG, Carmen CGB, Landa SC

Idioma: Ingles.
Referencias bibliográficas: 36
Paginas: 84-93
Archivo PDF: 1490.20 Kb.


RESUMEN

     


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kennel KB, Bozlar M, De Valk AF, Greten FR. Cancer-associated fibroblasts in inflammation and antitumor immunity. Clin Cancer Res. 2023; 29 (6): 1009-1016.

  2. Sánchez-Torres LJ, Santos-Hernández M. [The art of diagnosing bone tumors]. Acta Ortop Mex. 2012; 26 (1): 57-65.

  3. Latorre MR, Albergo JI, Farfalli GL, Roitman PD, Plantalech L, Ayerza MA et al. Denosumab como tratamiento neoadyuvante del tumor de células gigantes del hueso. Indicaciones, resultados y efectos adversos [Denosumab as a treatment for giant cell tumor of bone. Indications, results and side effects]. Medicina (B Aires). 2021; 81 (5): 767-773.

  4. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L et al. Bone metastases: an overview. Oncol Rev. 2017; 11 (1): 321.

  5. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12 (20 Pt 2): 6243s-6249s.

  6. Qian Y, Song X, Zhang K, Balakumaran A, Arellano J. Short-term disability in solid tumor patients with bone metastases and skeletal-related events. J Med Econ. 2015; 18 (3): 210-218.

  7. Hile ES, Fitzgerald GK, Studenski SA. Persistent mobility disability after neurotoxic chemotherapy. Phys Ther. 2010; 90 (11): 1649-1657.

  8. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013; 63 (6): 419-437.

  9. Castaneda M, den Hollander P, Kuburich NA, Rosen JM, Mani SA. Mechanisms of cancer metastasis. Semin Cancer Biol. 2022; 87: 17-31.

  10. Hashemzaei M, Delarami Far A, Yari A, Heravi RE, Tabrizian K, Taghdisi SM et al. Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo. Oncol Rep. 2017; 38 (2): 819-828.

  11. Riaz MK, Zhang X, Wong KH, Chen H, Liu Q, Chen X et al. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy. Int J Nanomedicine. 2019; 14: 2879-2902.

  12. Marure-Rojano AE, Cano-García JR, Luna-Agulo AB, Sánchez-Chapul L, Santos-Cuevas CL, Aguilar-Gaytán MDR et al. The cytotoxic effect of quercetin-induced apoptosis on lung metastatic cells from giant cell tumor of bone. Cell Mol Biol (Noisy-le-grand). 2025; 71 (5): 6-12.

  13. Reyes-Farias M, Carrasco-Pozo C. The Anti-cancer effect of quercetin: molecular implications in cancer metabolism. Int J Mol Sci. 2019; 20 (13): 3177.

  14. Valdespino-Gómez VM, Valdespino-Castillo PM, Valdespino-Castillo VE. Interacción de las vías de señalización intracelulares participantes en la proliferación celular: potencial blanco de intervencionismo terapéutico [Cell signaling pathways interaction in cellular proliferation: Potential target for therapeutic interventionism]. Cir Cir. 2015; 83 (2): 165-174.

  15. López-Oliva E. Efecto de flavonoides de origen vegetal sobre la vía del NO/GMPC. [Tesis de Maestría]. Universidad Juárez Autónoma de Tabasco. 2024.

  16. Cao X, He Y, Li X, Xu Y, Liu X. The IRE1α-XBP1 pathway function in hypoxia-induced pulmonary vascular remodeling, is upregulated by quercetin, inhibits apoptosis and partially reverses the effect of quercetin in PASMCs. Am J Transl Res. 2019; 11 (2): 641-654.

  17. González-Magaña A, Blanco FJ. Human PCNA structure, function, and interactions. Biomolecules. 2020; 10 (4): 570.

  18. Espinoza-Laparra M. Determinación del efecto de Calendula officinalis sobre los niveles de expresión de marcadores tumorales en cáncer de pulmón. [Tesis de Maestría]. Instituto Politécnico Nacional. 2011.

  19. Qiu X, Wang H, Wang Z, Fu Y, Yin J. Expression of PCNA, Ki-67 and COX-2 in breast cancer based on DCE-MRI image information. J Infect Public Health. 2020; 13 (12): 2032-2037.

  20. Yang C, Song J, Park S, Ham J, Park W, Park H et al. Targeting thymidylate synthase and tRNA-derived non-coding RNAs improves therapeutic sensitivity in colorectal cancer. Antioxidants (Basel). 2022; 11 (11): 2158.

  21. Yadav N, Tripathi AK, Parveen A, Parveen S, Banerjee M. PLGA-quercetin nano-formulation inhibits cancer progression via mitochondrial dependent caspase-3, 7 and independent FoxO1 activation with concomitant PI3K/AKT suppression. Pharmaceutics. 2022; 14 (7): 1326.

  22. Muñoz MM, Saavedra BA. Efectos anticancerígenos de los flavonoides quercetina y luteolina, con enfoque en el cáncer de ovario: Universidad de Talca (Chile). Escuela de Tecnología Médica.; 2020.

  23. Elinos-Báez CM, Maldonado V, Zajgla JM. Caspasas: moléculas inductoras de apoptosis. Gac Méd México. 2003; 139 (5): 493-499.

  24. Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019; 18 (1): 100.

  25. Ju E, Park KA, Shen HM, Hur GM. The resurrection of RIP kinase 1 as an early cell death checkpoint regulator-a potential target for therapy in the necroptosis era. Exp Mol Med. 2022; 54 (9): 1401-1411.

  26. García-Aguiar JI. Caracterización del complejo asociado al receptor 1 del factor de necrosis tumoral en dos líneas celulares HPV-16+ con resistencia diferencial a la apoptosis. [Tesis] 2018.

  27. DeRoo E, Zhou T, Liu B. The role of RIPK1 and RIPK3 in cardiovascular disease. Int J Mol Sci. 2020; 21 (21): 8174.

  28. Degterev A, Ofengeim D, Yuan J. Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci USA. 2019; 116 (20): 9714-9722.

  29. Martínez-Ezquerro JD, Herrera LA. Angiogénesis: VEGF/VEGFRs como blancos terapéuticos en el tratamiento contra el cáncer. Cancerología. 2006; 1 (1): 83-96.

  30. Saavedra Garrido P. Resveratrol como coadyuvante en el tratamiento del cáncer. [Tesis] 2016.

  31. Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021; 101 (3): 797-855.

  32. Nguyen MV, Carlier C, Nich C, Gouin F, Crenn V. Fracture risk of long bone metastases: a review of current and new decision-making tools for prophylactic surgery. Cancers (Basel). 2021; 13 (15): 3662.

  33. Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G et al. Chemotherapy-induced neuropathy in cancer survivors. J Pain Symptom Manage. 2017; 54 (2): 204-218.e2.

  34. McNeish BL, Dittus K, Mossburg J, Krant N, Steinharter JA, Feb K et al. The association of chemotherapy-induced peripheral neuropathy with reduced executive function in chemotherapy-treated cancer survivors: a cross-sectional study. J Geriatr Oncol. 2024; 15 (4): 101765.

  35. Cao C, Yang L, Schmitz KH, Ligibel JA. Prevalence and cancer-specific patterns of functional disability among us cancer survivors, 2017-2022. J Clin Oncol. 2024; 42 (19): 2257-2270.

  36. Cheville AL, Murthy NS, Basford JR, Rose PS, Tran K, Pittelkow TP et al. Imaging and clinical characteristics predict near-term disablement from bone metastases: implications for rehabilitation. Arch Phys Med Rehabil. 2016; 97 (1): 53-60.




2020     |     www.medigraphic.com